N
N. Mairon
Researcher at Hoffmann-La Roche
Publications - 11
Citations - 3373
N. Mairon is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Tolerability & Ibandronic acid. The author has an hindex of 6, co-authored 11 publications receiving 2658 citations.
Papers
More filters
Journal ArticleDOI
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Xavier Montalban,Stephen L. Hauser,Ludwig Kappos,Douglas L. Arnold,Amit Bar-Or,Giancarlo Comi,Jérôme De Seze,Gavin Giovannoni,Hans-Peter Hartung,Bernhard Hemmer,Fred D. Lublin,Kottil Rammohan,Krzysztof Selmaj,Anthony Traboulsee,Annette Sauter,Donna Masterman,Paulo Fontoura,Shibeshih Belachew,Hideki Garren,N. Mairon,Peter Chin,Jerry S. Wolinsky +21 more
TL;DR: Among patients with primary progressive multiple sclerosis, ocrelizumab was associated with lower rates of clinical and MRI progression than placebo; there was no clinically significant difference between groups in the rates of serious adverse events and serious infections.
Journal ArticleDOI
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Stephen L. Hauser,Amit Bar-Or,Giancarlo Comi,Gavin Giovannoni,Hans Peter Hartung,Bernhard Hemmer,Fred D. Lublin,Xavier Montalban,Kottil Rammohan,Krzysztof Selmaj,A. Traboulsee,Jerry S. Wolinsky,Douglas L. Arnold,Gaelle Klingelschmitt,Donna Masterman,Paulo Fontoura,Shibeshih Belachew,Peter Chin,N. Mairon,Hideki Garren,Ludwig Kappos +20 more
TL;DR: Among patients with relapsing multiple sclerosis, ocrelizumab was associated with lower rates of disease activity and progression than interferon beta‐1a over a period of 96 weeks.
Journal ArticleDOI
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
Paul D. Miller,Michael R. McClung,Liviu Macovei,J. A. Stakkestad,Marjorie M. Luckey,B. Bonvoisin,Jean-Yves Reginster,Robert R. Recker,C. Hughes,E. Michael Lewiecki,Dieter Felsenberg,Pierre D. Delmas,David L. Kendler,M. A. Bolognese,N. Mairon,Cyrus Cooper +15 more
TL;DR: Once‐monthly (50/50, 100, and 150 mg) and daily (2.5 mg; 3‐year vertebral fracture risk reduction: 52%) oral ibandronate regimens were compared in 1609 women with postmenopausal osteoporosis.
Journal ArticleDOI
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study
J-Y Reginster,Silvano Adami,Peter L. Lakatos,Maria Greenwald,Jan J. Stepan,Stuart L. Silverman,Claus Christiansen,Lucy Rowell,N. Mairon,B. Bonvoisin,Marc K. Drezner,Ronald Emkey,Dieter Felsenberg,Cyrus Cooper,Pierre D. Delmas,Paul D. Miller +15 more
TL;DR: Once-monthly oral ibandronate is at least as effective and well tolerated as daily treatment and may be more convenient for patients and improve therapeutic adherence, thereby optimising outcomes.
Journal Article
Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.
John A. Eisman,Roberto Civitelli,Silvano Adami,Edward Czerwiński,Chris Recknor,Richard L. Prince,Jean-Yves Reginster,Mone Zaidi,Dieter Felsenberg,C. Hughes,N. Mairon,Daiva Masanauskaite,David M. Reid,Pierre D. Delmas,Pierre D. Delmas,Robert R. Recker +15 more
TL;DR: Ibandronate IV injections are an effective and well tolerated treatment for postmenopausal osteoporosis and provide a useful alternative to oral dosing.